Smith & Nephew 

$13.10
602
-$1.40-9.66% Monday 20:00

統計

當日最高
14.5
當日最低
14.5
52週高點
18.5
52週低點
13.1
成交量
1,000
平均成交量
1,277
市值
5.53B
本益比
18.19
股息殖利率
2.98%
股息
0.39

即將到來

股息

2.98%股息殖利率
May 26
$0.24
Nov 25
$0.15
May 25
$0.23
Nov 24
$0.14
May 24
$0.23
10年成長
2.39%
5年成長
1.45%
3年成長
-1.46%
1年成長
2.05%

財報

4Aug預期
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
下一步
0
0.2
0.39
0.59
預期EPS
0.47
實際EPS
不適用

財務

10.14%利潤率
有盈利
2020
2021
2022
2023
2024
2025
6.16B營收
625M淨利

分析師評級

30.00平均目標價
最高預估為 30.00。
來自過去6個月內的 1 則評分。這不是投資建議。
買入
0%
持有
100%
賣出
0%

其他人也在關注

此清單是根據在 Stock Events 上追蹤 SNNUF 的使用者自選建立的。這不是投資建議。

競爭對手

此清單為基於近期市場事件的分析。並非投資建議。

關於

Smith & Nephew plc is a global medical technology enterprise dedicated to the development, manufacturing, and worldwide commercialization of an extensive array of medical devices. Its product portfolio spans several key areas. In orthopedics, the company provides knee implants for replacement procedures, hip implants for joint reconstruction, and trauma and extremities products, including both internal and external fixation devices, crucial for stabilizing severe fractures and correcting deformities. For sports medicine, Smith & Nephew offers joint repair solutions tailored for surgeons. This includes specialized instruments, advanced technologies, and implants essential for minimally invasive joint surgeries, targeting soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, the firm supplies arthroscopic enabling technologies that enhance surgical visualization and intervention within joints. This suite encompasses fluid management equipment for surgical access, high-definition cameras, digital imaging capture systems, scopes, light sources, and monitors. It also features radiofrequency, electromechanical, and mechanical tissue resection devices, alongside hand instruments for precise tissue removal. The company also provides dedicated ear, nose, and throat (ENT) solutions. Its Advanced Wound Management division delivers comprehensive solutions for the treatment and prevention of acute and chronic wounds, covering conditions like leg, diabetic, and pressure ulcers, burns, and post-operative wounds. This segment includes advanced wound bioactives, comprising biologics and other bioactive technologies for debridement, dermal repair, and regeneration. Regenerative medicine products, such as skin, bone graft, and articular cartilage substitutes, are also offered. Furthermore, Smith & Nephew provides advanced wound devices, including traditional and single-use negative pressure wound therapy systems, and hydrosurgery technology. Primarily serving healthcare providers globally, Smith & Nephew plc was founded in 1856 and is headquartered in Watford, United Kingdom.
Show more...
執行長
Dr. Deepak S. Nath Ph.D.
員工
17349
國家
英國
ISIN
GB0009223206

上市

0 Comments

分享你的想法

FAQ

Smith & Nephew 今天的股價是多少?
SNNUF 目前價格為 $13.10 USD,過去 24 小時下跌了 -9.66%。在圖表上更密切關注 Smith & Nephew 股票的表現。
Smith & Nephew 的股票代號是什麼?
根據交易所不同,股票代號可能會有所差異。例如,在 交易所,Smith & Nephew 的股票以代號 SNNUF 進行交易。
Smith & Nephew 的股價在上漲嗎?
SNNUF 股票較上週上漲 +0%,本月下跌 -12.14%,過去一年 Smith & Nephew 下跌 -14.71%。
Smith & Nephew 的市值是多少?
今天 Smith & Nephew 的市值為 5.53B
Smith & Nephew 下一次財報日期是什麼時候?
Smith & Nephew 將於 August 04, 2026 公布下一次財報。
Smith & Nephew 上一季度的財報如何?
SNNUF 上一季度的財報為每股 0.59 USD,預估為 0.58 USD,帶來 +2.16% 的驚喜。下一季度的預估財報為每股 不適用 USD。
Smith & Nephew 去年的營收是多少?
Smith & Nephew 去年的營收為 6.16BUSD。
Smith & Nephew 去年的淨利是多少?
SNNUF 去年的淨收益為 625MUSD。
Smith & Nephew 會發放股息嗎?
是的,SNNUF 的股息每 半年一次 發放一次。每股最新股息為 0.24 USD。截至今日,股息殖利率(FWD)% 為 2.98%。
Smith & Nephew 有多少名員工?
截至 July 06, 2026,公司共有 17,349 名員工。
Smith & Nephew 位於哪個產業?
Smith & Nephew從事於Health & Wellness產業。
Smith & Nephew 何時完成拆股?
Smith & Nephew 上次拆股發生於 October 15, 2014,比例為 2.5:1。
Smith & Nephew 的總部在哪裡?
Smith & Nephew 的總部位於 英國 的 Watford。